Login / Signup

Mitigating Immunogenicity by Coordinating Botulinum Toxin Treatments Between Aesthetics and Therapeutics.

Stephen M GollompSaami KhalifianSamantha Gokhale
Published in: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] (2024)
Physicians have a responsibility to incorporate risk management and open dialog into their BoNT treatment plans to maximize effectiveness and longevity of treatments.
Keyphrases
  • botulinum toxin
  • primary care
  • randomized controlled trial
  • systematic review
  • minimally invasive
  • small molecule
  • health insurance
  • replacement therapy